The Anti-Depressant Cymbalta Can Help Manage Peripheral Neuropathy From Chemotherapy
In a study presented at ASCO, researchers found that the drug duloxetine (Cymbalta) can help to treat peripheral neuropathy, a painful side effect of chemotherapy using taxanes. Taxotere, the chemotherapy drug used to treat castrate [...]
New Site Added for the Early/Expanded Access Trial of Enzalutamide (MDV-3100)
The Early/Expanded Access Committee has announced the addition of a new site in Atlanta, Ga for the trial of MDV-3100. According to my sources, there will be even more sites added in the near future. [...]
New Research Contradicts Prior Understanding – Intermittent Hormone Therapy for Prostate Cancer Inferior to Continuous Therapy
At the American Society for Clinical Oncology's (ASCO) meeting there was an upsetting plenary presentation made on June 3. Data was presented by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive [...]
From ASCO: Enzalutamide (MDV-3100) Data Relating to Quality of Life Measures and Extension of Time to First Skeletal-Related Event
The American Society of Clinical Oncologists (ASCO) has started their annual conference in Chicago. I am anticipating a number of interesting and important abstracts that will be directly relevant to those of us with advanced [...]
Important Additional Information About Early/Expanded Access to Enzalutamide (MDV-3100)
I now have some additional information about the Early/Expanded Access Program for Enzalutamide (MDV-3100)for men with advanced prostate cancer. Jan Manarite, who is a member of the Early Access Committee has provided the following information: [...]
Breaking News- MDV-3100 Starts an Expanded Access Program in the United States
Medivation and Astellas Announce Initiation of Expanded Access Program for Enzalutamide (MDV3100) in the United States for men with metastatic prostate cancer previously treated with chemotherapy. Medivation, Inc. and Astellas Pharma Inc. today announced that [...]